OPKO Health Q3 EPS Estimate Reduced by Barrington Research

Key Points

• Barrington Research has cut its Q3 2025 EPS estimate for OPKO Health from ($0.04) to ($0.06), while maintaining an "Outperform" rating with a price target of $2.25.
• In its latest quarterly results, OPKO Health reported an EPS of ($0.19), missing estimates by ($0.07) and experiencing a 13.9% drop in revenue year-over-year.
• OPKO Health currently has a consensus rating of "Moderate Buy" with an average price target of $2.75.

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Stock analysts at Barrington Research lowered their Q3 2025 earnings per share estimates for shares of OPKO Health in a report issued on Monday, August 4th. Barrington Research analyst M. Petusky now expects that the biotechnology company will earn ($0.06) per share for the quarter, down from their previous forecast of ($0.04). Barrington Research currently has a "Outperform" rating and a $2.25 price target on the stock. The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share. Barrington Research also issued estimates for OPKO Health's Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.13) EPS and FY2027 earnings at ($0.11) EPS.

OPKO Health (NASDAQ:OPK - Get Free Report) last issued its earnings results on Thursday, July 31st. The biotechnology company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.07). OPKO Health had a negative return on equity of 13.17% and a negative net margin of 26.68%. The company had revenue of $156.80 million during the quarter, compared to analysts' expectations of $165.74 million. During the same quarter in the previous year, the company earned ($0.01) EPS. The firm's quarterly revenue was down 13.9% compared to the same quarter last year.

OPK has been the topic of several other research reports. Wall Street Zen lowered shares of OPKO Health from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. JPMorgan Chase & Co. started coverage on OPKO Health in a research report on Friday, April 25th. They issued a "neutral" rating on the stock. Finally, LADENBURG THALM/SH SH upgraded shares of OPKO Health to a "strong-buy" rating in a research note on Tuesday, July 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $2.75.

OPKO Health Price Performance

Shares of NASDAQ:OPK traded up $0.02 during trading on Wednesday, reaching $1.25. 3,543,196 shares of the company's stock traded hands, compared to its average volume of 2,999,738. OPKO Health has a fifty-two week low of $1.11 and a fifty-two week high of $2.04. The company has a quick ratio of 3.02, a current ratio of 3.41 and a debt-to-equity ratio of 0.25. The firm has a market cap of $992.23 million, a PE ratio of -5.00 and a beta of 1.19. The company has a 50-day simple moving average of $1.33 and a 200-day simple moving average of $1.47.

Institutional Trading of OPKO Health

A number of hedge funds have recently bought and sold shares of OPK. Oak Thistle LLC acquired a new position in shares of OPKO Health in the 1st quarter valued at $26,000. GM Advisory Group LLC acquired a new position in shares of OPKO Health in the 1st quarter valued at $33,000. Cerity Partners LLC acquired a new position in shares of OPKO Health in the 1st quarter valued at $36,000. Kapitalo Investimentos Ltda acquired a new position in shares of OPKO Health in the 2nd quarter valued at $41,000. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of OPKO Health by 75.3% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 28,908 shares of the biotechnology company's stock valued at $42,000 after purchasing an additional 12,417 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company's stock.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 675,000 shares of the company's stock in a transaction dated Friday, August 8th. The stock was acquired at an average cost of $1.32 per share, with a total value of $891,000.00. Following the purchase, the chief executive officer directly owned 214,676,448 shares in the company, valued at approximately $283,372,911.36. This trade represents a 0.32% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 49.69% of the company's stock.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.